News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MycoLogics, Inc. Focuses On The Isolation Of New Classes Of Compounds For Treatment Of Human Fungal Disease



10/19/2005 5:10:11 PM

MycoLogics, Inc., an innovative biotechnology company specializing in the development of therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, today announced award of a Phase I SBIR grant by the Department of Health and Human Services to isolate a new class of compounds to treat human fungal disease by disrupting beta(1,6)-glucan synthesis. The beta(1,6)-glucan polymer is an essential component for fungal growth, it is found in fungi not in humans and, therefore is an excellent target for the development of antifungal drugs.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES